20/20 GeneSystems, Inc.
20/20 GeneSystems, headquartered in Rockville, Maryland (outside of Washington, D.C.), is a revenue stage diagnostics company that uses machine learning algorithms to greatly improve the accuracy of laboratory tests for the early detection of cancer and other diseases. In the most recent calendar year our revenues grew to over $2 million aided by several COVID-19 tests that we are successfully commercializing.
Our multi-cancer early detection blood test (www.OneTest.Ai) measures tumor antigens and uses a machine learning algorithm powered by outcome data from over 230,000 individuals tested in real-world screening settings. OneTest is a highly accessible and affordable pre-test that can be followed up with more expensive and specific circulating tumor DNA tests such as those being developed by Grail and Thrive Earlier Detection. (Those companies were recently acquired for $8 billion and $2 billion respectively.)
20/20’s institutional investors include Ping An, one of the largest digital health and insurance companies in China, and several well-regarded American funds. We are working to an initial public offering in 2021 and are now lining up IPO “crossover” investors.
Mr. Jonathan Cohen
CEORichard Brand
CFOJiming Zhou
COO3E BioVentures
3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency.
The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.
Mr. Lei Liu
Director3S Pharmaceutical Group
3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.
3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.
We look forward to having opportunity to discuss potential collaboration with you.
Zhao Peng
Senior BD ManagerAbiocenter (Beijing) Biotechnology Co., Ltd.
Penghui Xie
CEOable cerebral, llc
ACL is a bio-pharmaceutical and medical device company with patented (US & China) technologies and products.
We have achieved our first goal via BrainGlucoseTM by providing timed release of brain energy as circadian therapy to eliminate nightmares, night sweating, hallucinations, which have been saving lives and dignity of many early and mid-stage Alzheimer’s patients; and to help diabetics to avoid nocturnal hypoglycemia for better sleep and protection from seizures, coma or even death.
More excitingly, through communications with FDA and experts in biopharmaceutical fields, we are initiating for phase III clinical study inquiry for our delayed and sustained release of energy product as breakthrough new drug status for Alzheimer’s disease.
We are also looking for investment or partnership to advance our game changing technology product, a noninvasive medical device, AddMemTM, which will be also the world’s first ever product for memory consolidation and recovery.
ACL is also a licensed manufacturer for medical food in Pennsylvania.
Our product can be marketed in China through registration with Chinese FDA as “special medical formulated food”, or apply as a new drug.